Skip to main content
Journal cover image

Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics

Publication ,  Journal Article
Yerges-Armstrong, LM; Ellero-Simatos, S; Georgiades, A; Zhu, H; Lewis, JP; Horenstein, RB; Beitelshees, AL; Dane, A; Reijmers, T; Hankemeier, T ...
Published in: Clinical Pharmacology and Therapeutics
2013

Although aspirin is a well-established antiplatelet agent, the mechanisms of aspirin resistance remain poorly understood. Metabolomics allows for measurement of hundreds of small molecules in biological samples, enabling detailed mapping of pathways involved in drug response. We defined the metabolic signature of aspirin exposure in subjects from the Heredity and Phenotype Intervention Heart Study. Many metabolites, including known aspirin catabolites, changed on exposure to aspirin, and pathway enrichment analysis identified purine metabolism as significantly affected by drug exposure. Furthermore, purines were associated with aspirin response, and poor responders had higher postaspirin adenosine and inosine levels than did good responders (n = 76; both P < 4 × 10-3). Using our established " pharmacometabolomics-informed pharmacogenomics" approach, we identified genetic variants in adenosine kinase associated with aspirin response. Combining metabolomics and genomics allowed for more comprehensive interrogation of mechanisms of variation in aspirin response-an important step toward personalized treatment approaches for cardiovascular disease. © 2013 American Society for Clinical Pharmacology and Therapeutics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clinical Pharmacology and Therapeutics

DOI

ISSN

0009-9236

Publication Date

2013

Volume

94

Issue

4

Start / End Page

525 / 532

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yerges-Armstrong, L. M., Ellero-Simatos, S., Georgiades, A., Zhu, H., Lewis, J. P., Horenstein, R. B., … Kaddurah-Daouk, R. (2013). Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics, 94(4), 525–532. https://doi.org/10.1038/clpt.2013.119
Yerges-Armstrong, L. M., S. Ellero-Simatos, A. Georgiades, H. Zhu, J. P. Lewis, R. B. Horenstein, A. L. Beitelshees, et al. “Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics.” Clinical Pharmacology and Therapeutics 94, no. 4 (2013): 525–32. https://doi.org/10.1038/clpt.2013.119.
Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics. 2013;94(4):525–32.
Yerges-Armstrong, L. M., et al. “Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics.” Clinical Pharmacology and Therapeutics, vol. 94, no. 4, 2013, pp. 525–32. Scival, doi:10.1038/clpt.2013.119.
Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, Beitelshees AL, Dane A, Reijmers T, Hankemeier T, Fiehn O, Shuldiner AR, Kaddurah-Daouk R. Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics. 2013;94(4):525–532.
Journal cover image

Published In

Clinical Pharmacology and Therapeutics

DOI

ISSN

0009-9236

Publication Date

2013

Volume

94

Issue

4

Start / End Page

525 / 532

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences